obviousness

Procter & Gamble Wins Patent Infringement Lawsuit for Osteoporosis Therapy Actonel

... in Actonel. Teva sought to market a generic version of Actonel in the United States under the assertion that the Actonel patent was not valid due to obviousness of the invention. On February 28, 2008, the Court ruled in favor of P&G, expressly rejecting Teva's validity challenge. Shortly afterwards, Teva ...

CoolTouch Inc. Responds to Cynosure Patent Infringement Lawsuit

...in the early 1990s on laser-assisted lipolysis and the Paolini patent claims are obvious, invalidating the patent. The recent Supreme Court rulings on obviousness may also play a role in invalidating these patents. "We welcome the opportunity to establish the facts with respect to patents that Cynosure claims ...

obviousness in Biological Technology

High court sends message on patent obviousness

One of the primary burdens facing a patent applicant before the United States Patent and Trademark Office is the requirement that the claimed invention is not obvious under 35 U.S.C. 103. Similarly, obviousness is a typical defense raised in patent infringement cases. Yet, overcoming obviousne...

Inventions could fall prey to Monday morning quarterbacking

...the inventor, and any change in the legal test for obviousness would profoundly impact the ability to procure and...rt (i.e., known technology) in order to sustain an obviousness rejection of an application for patent. The Co...opeans Interestingly, the present standard for obviousness in Europe, which is referred to as "inventive step...

Is Wisconsin's stem cell standing diminished?

...ng patentability standard for obviousness. Any change in the legal test for obviousness would impact the ability to procure and enforce patents. As part of the ...n, or motivation in the prior art (known technology) in order to sustain an obviousness rejection of a patent application. Dan Ravicher, executive director of t...

Supreme Court ruling seen as blow to WARF stem cell patents

...holders, said John Simpson, stem cell project director for the FTCR. The decision is part of a trend in the Supreme Court to swing back the other way. obviousness will now be easier to prove. The FTCR, which has called on WARF managing director Carl Gulbrandsen to resign from the U.S. Patent Public Advisory C...